Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Company Overview - Exelixis, Inc. is an oncology-focused biotechnology company based in Alameda, CA, specializing in the discovery, development, and commercialization of new drugs for difficult-to-treat cancers [11] - The company is leveraging investments, expertise, and strategic partnerships to target a broad range of tumor types and indications with its differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics [11] Investment Ratings - Exelixis is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12] - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 15.5% for the current fiscal year [12] - One analyst has revised their earnings estimate upwards in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0 to $2.31 per share [12] Performance Metrics - Exelixis boasts an average earnings surprise of 48.6%, suggesting strong performance relative to expectations [12] - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Exelixis is positioned as a potential top pick for growth investors [13]